Therapy Areas: Devices
Ethicon's Biopatch Chlorhexidine-impregnated Dressings Receive Highest Recommendation from CDC for Prevention of Intravascular Catheter-related Infections
13 November 2017 - - Specific Chlorhexidine-impregnated dressings from Somerville, New Jersey-based surgical technologies and solutions company Ethicon, part of the Johnson and Johnson Medical Devices Companies, have received the strongest evidence-based recommendation in the Centers for Disease Control (CDC) updated guideline on use of chlorhexidine impregnated dressings for prevention of intravascular catheter-related infections, the company said.
Biopatch Protective Disk with CHG meets the updated CDC recommendation requirements, and continues as the standard of care for reducing intravascular catheter-related blood stream infections.
Biopatch is the only IV dressing proven in multiple meta-analyses and randomized controlled trials to reduce risk of central line associated bloodstream infections in patients with central and arterial lines.
The new CDC guideline says: "For patients aged 18 years and older: Chlorhexidine-impregnated dressings with an FDA-cleared label that specifies a clinical indication for reducing catheter-related bloodstream infection (CRBSI) or catheter-associated bloodstream infection (CABSI) are recommended to protect the insertion site of short-term, non-tunneled central venous catheters."
Ethicon, part of the Johnson and Johnson Medical Devices Companies, is dedicated to addressing pressing health care issues to improve and save lives. Its surgical technologies and solutions, include sutures, staplers, energy devices, trocars, hemostats, and infection prevention solutions.
Login
Username:

Password: